NurExone Signs Letter of Intent with Nanometrix for its AI-Based Exosome and Cargo Molecular Profiling Technology
The two companies will collaborate to improve NurExone’s drug development stages, from R&D to quality assurance
The Company will host an Investor Webinar on Thursday, October 20, 2022 at 11:00 a.m. EST
Calgary, Alberta and Oxford, UK–(Newsfile Corp. – October 12, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically guided exosome for patients with traumatic spinal cord injury, is pleased to announce that the Company’s wholly owned subsidiary, NurExone Biologic Ltd., has signed a non-binding letter of intent for collaboration (the “collaboration”) with Nanometrix Ltd. (“Nanometrix”), a UK-based nanoparticle analysis company that provides services to profile exosome molecules and their cargo.
As part of the collaboration, exosomes and cargo samples from NurExone will be processed and analyzed by Nanometrix, which will use its proprietary artificial intelligence (AI) software to extract and analyze morphological and demographic data for profiling. detailed molecular analysis of exosomes and to quantify siRNA cargo copy. number per extracellular vesicle (EV), information that was out of reach.
“Detailed molecular profiling of our exosomes and their siRNA cargo will facilitate a quality assurance program for reproducible mass production of ExoTherapies for commercialization,” said Dr. Lior Shaltiel, CEO of NurExone. “Nanometrix has the expertise and resources to perform this analysis in a highly professional manner and we look forward to working with them.”
“The signing of this letter of intent is a first step towards an important milestone for Nanometrix”, said Alexandre Kitching, CEO and co-founder of Nanometrix. “We are excited to begin this collaboration with NurExone as we believe in the future of exosomes as an advanced platform for drug delivery. We look forward to deploying our technology and helping NurExone gain insights on their siRNA-loaded exosomes and subsequently improving the various stages of their drug development process.”
Exosomes are best defined as electrical vehicles that have emerged as promising guided nanocarriers for drug delivery and targeted therapy, and as alternatives to stem cell therapy. EVs are small membrane vesicles derived from endosomes, approximately 30–150 nanometers in diameter, and are released into extracellular fluids by cells in all living systems. They are well suited for the delivery of functional small molecules, and growing evidence indicates that they have a central role in cell-to-cell communication.
NurExone’s ExoTherapy uses proprietary exosomes as biologically guided nanocarriers to deliver specialized therapeutic compounds to targeted areas. The molecules delivered promote an environment that induces a healing process at the target location. For its first clinical indication for recovery of function in patients with traumatic spinal cord injury (SCI), NurExone used engineered siRNA sequences as delivered therapeutic molecules.
ExoTherapy is being developed as a revolutionary “ready to use” intranasal product to treat traumatic spinal cord and brain injuries as well as other central nervous system indications. In preclinical studies in rats with a completely severed spinal cord, intranasal administration of ExoPTEN resulted in significant motor improvement, sensory recovery, and faster restoration of urinary reflexes.
Webinar for investors
The Company will host a webinar to discuss its recent business highlights and growth prospects on Thursday, October 20, 2022 at 11:00 a.m. EST.
Please click on the link below to register for the webinar.
Nanometrix is a nanoparticle analysis start-up based in Oxford, UK, which has developed unique end-to-end services to routinely create molecular profiles of nanoparticles from samples. Each profile delivers information currently out of reach such as morphology, population dynamics and cargo copy number per nanoparticle. Nanometrix software and services are currently deployed in laboratories and teams working around the world to develop new treatments and diagnostics.
About NurExone Biological Inc.
NurExone Biologic Inc. is a TSX Venture Exchange-listed pharmaceutical company developing a biology-guided exotherapy platform to be delivered non-invasively to patients with traumatic spinal cord injuries. Exotherapy has been conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is bringing the treatment to humans and the company holds an exclusive worldwide license from Technion to develop and commercialize the technology.
For more information please contact:
Email: [email protected]
This press release contains certain forward-looking statements, including statements regarding the Company’s future plans, the Letter of Intent, the development activities to be carried out within the framework of the Collaboration, the possible conclusion of a commercial agreement between the parties and future manufacturing plans and marketing activities. Where possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, ” believes”, “estimates”, “predicts” or “potential” or the negative form or other variations of these words, or similar words or expressions, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as of the date hereof. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s early stage of development, lack of revenues to date, government regulation, market acceptance of its products, future rapid technological development, dependence on key personnel, protection of intellectual property and dependence on the Company’s strategic partners. These factors should be carefully considered and readers should not place undue reliance on forward-looking statements. Although the forward-looking statements contained in this press release are based on what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company undertakes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
NurExone provides an updated version of the previously released version earlier today to remove a paragraph that was mistakenly included.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/140289